Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Macarulla Mercade, T. [1 ,2 ]
Wang-Gillam, A. [3 ]
Chen, L. [4 ]
Blanc, J. [5 ]
Lee, K. [6 ]
Bodoky, G. [7 ]
Dean, A. [8 ]
Siveke, J. [9 ,10 ,11 ]
Mirakhur, B. [12 ]
Chen, J. [13 ]
de Jong, F. [14 ]
机构：
[1] Vall dHebron Univ Hosp HUVH, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Washington Univ, Div Oncol, St Louis, MO USA
[4] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan
[5] Hop Haut Leveque, Bordeaux, France
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Szent Laszlo Hosp, Dept Oncol, Budapest, Hungary
[8] St John God Hosp Subiaco, Subiaco, WA, Australia
[9] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[10] German Canc Consortium DKTK, Essen, Germany
[11] German Canc Res Ctr, Essen, Germany
[12] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[13] Shire Plc, Cambridge, MA USA
[14] Shire Int GmbH, Glattpk Opfikon, Switzerland
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 150
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Lee, K.
    Bodoky, G.
    Blanc, J.
    Siveke, J.
    Macarulla Mercade, T.
    Wang-Gillam, A.
    Chen, L.
    Mirakhur, B.
    Chen, J.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
    Lakatos, G.
    Lee, K.
    Siveke, J.
    Blanc, J.
    Macarulla Mercadé, T.
    Dean, A.
    Bodoky, G.
    Mirakhur, B.
    Chen, J.
    Wang-Gillam, A.
    Chen, L.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 42 - 42
  • [3] NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Mercade, T. Macarulla
    Bodoky, G.
    Siveke, J.
    Lee, K-H.
    Chen, J.
    Mirakhur, B.
    Dean, A.
    Chen, L-T.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial
    Macarulla Mercade, T.
    Lee, K.
    Lakatos, G.
    Wang-Gillam, A.
    Chen, L.
    Mirakhur, B.
    De Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1
    Chen, Li-Tzong
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Bekaii-Saab, Tanios
    Siveke, Jens T.
    PANCREATOLOGY, 2021, 21 (01) : 192 - 199
  • [6] Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine
    Hubner, R.
    Cubillo, A.
    Blanc, J. -F.
    Melisi, D.
    Von Hoff, D.
    Wang-Gillam, A.
    Chen, L. -T.
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    De Jong, F.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 119 - 119
  • [7] The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Macarulla Mercade, T.
    Wang-Gillam, A.
    Chen, L.
    Blanc, J.
    Lee, K.
    Bodoky, G.
    Dean, A.
    Chen, J.
    Mirakhur, B.
    Siveke, J.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3
    Abdelrahim, Maen
    Khan, Gazala
    Hatoum, Hassan
    Zervoudakis, Alice
    Dayyani, Farshid
    Zhang, Li
    Li, Jia
    Maxwell, Fiona
    O'Reilly, Eileen M.
    Wainberg, Zev A.
    Peters, Mary Linton Bounetheau
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 717 - 717
  • [9] Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
    Bang, Yung-Jue
    Li, Chung-Pin
    Lee, Kyung-Hun
    Chiu, Chang-Fang
    Park, Joon Oh
    Shan, Yan-Shen
    Kim, Jun Suk
    Chen, Jen-Shi
    Shim, Hyun-Jeong
    Rau, Kun-Ming
    Choi, Hye Jin
    Oh, Do-Youn
    Belanger, Bruce
    Chen, Li-Tzong
    CANCER SCIENCE, 2020, 111 (02) : 513 - 527
  • [10] Real-world one-year overall survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan in the NAPOLI-1 based regimen.
    Kim, George P.
    Cockrum, Paul
    Surinach, Andy
    Abushahin, Laith, I
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345